PINC Stock Cash Flow Statements

Premier Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Premier Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31

operating activities
net income	17,881,000	26,842,000	-85,226,000	71,336,000	60,605,000	-49,162,000	52,866,000	42,410,000	18,905,000	48,649,000	64,374,000	42,959,000	30,711,000	39,069,000	77,232,000	121,306,000	27,551,000	51,444,000	44,904,000	180,685,000	55,445,000	73,217,000	92,189,000	71,329,000	23,493,000	73,802,000	104,811,000	81,973,000	100,636,000	76,549,000	19,769,000	60,616,000	140,568,000	72,139,000	178,675,000	58,095,000	50,356,000	71,557,000	60,995,000	52,253,000	32,061,000	72,029,000	65,808,000	64,887,000	66,632,000	101,980,000
adjustments to reconcile net income to net cash from operating activities:
net income (income) from discontinued operations, net of tax	137,000	771,000	39,389,000	1,604,000
depreciation and amortization	29,551,000	29,253,000	29,539,000	29,288,000	30,430,000	32,777,000	32,779,000	33,016,000	33,225,000	32,191,000	34,486,000	33,891,000	33,343,000	32,559,000	31,720,000	31,485,000	31,294,000	29,737,000	29,353,000	30,678,000	38,189,000	39,743,000	37,316,000	37,579,000	34,212,000	36,225,000	35,582,000	34,145,000	32,761,000	32,466,000	31,127,000	30,405,000	29,453,000	29,182,000	25,349,000	23,227,000	22,924,000	21,850,000	21,470,000	17,912,000	14,617,000	14,091,000	14,403,000	11,211,000	10,713,000	10,198,000
equity in net (income) loss of unconsolidated affiliates	-123,000	-514,000	-9,502,000	-1,833,000
deferred income taxes	8,062,000	12,950,000	-18,890,000	24,954,000	29,539,000	2,821,000	-11,498,000	-143,435,000	69,320,000	124,000	-197,000	2,156,000	19,866,000	17,036,000	1,190,000	18,700,000	39,615,000	4,228,000	2,008,000	-129,543,000	7,586,000	7,026,000	55,353,000	-1,985,000	4,131,000	5,104,000	-1,945,000	4,588,000	-10,560,000	7,902,000	227,350,000	8,298,000	-52,107,000	-3,545,000	99,140,000	17,074,000	3,369,000	1,014,000	8,134,000	13,197,000
stock-based compensation	7,564,000	6,071,000	2,588,000	6,931,000	75,000	8,145,000	8,378,000	6,692,000	-2,641,000	6,560,000	2,679,000	7,136,000	8,437,000	14,004,000	16,234,000	7,554,000	7,824,000	13,056,000	7,316,000	7,229,000	1,658,000	7,569,000	7,775,000	3,704,000	8,309,000	6,781,000	7,716,000	6,195,000	4,478,000	7,231,000	8,884,000	8,815,000	7,345,000	7,059,000	6,266,000	5,800,000	11,885,000	11,763,000	11,475,000	13,547,000	7,369,000	7,285,000	7,405,000	6,439,000	6,358,000	6,299,000
impairment of assets	10,810,000	6,853,000			0
other	306,000	-16,687,000	-8,327,000	1,672,000	3,135,000	-10,619,000	-493,000	3,459,000	3,435,000	-7,101,000	132,000	10,035,000	1,225,000	3,648,000	412,000	518,000	8,821,000	214,000	122,000	201,000
changes in operating assets and liabilities, net of the effects of acquisitions:
accounts receivable	-6,170,000	14,188,000	-7,228,000	2,216,000	-5,535,000	1,141,000	-20,178,000	13,173,000
contract assets	15,682,000	-3,675,000	16,116,000	-10,566,000	-1,572,000	-4,515,000	-16,340,000	-16,838,000	-9,113,000	-5,517,000	-14,602,000	-11,856,000	-8,080,000	-16,176,000	-17,087,000	-5,876,000	-7,952,000	-20,192,000	6,027,000	-29,568,000	20,704,000	-19,563,000	-578,000	-8,768,000
prepaid expenses and other assets	1,766,000	1,794,000	5,191,000	8,730,000	-5,252,000	9,956,000	-19,840,000	9,216,000
accounts payable	-148,000	757,000	-4,114,000	397,000	-6,956,000	13,065,000	5,707,000	-3,099,000
revenue share obligations	16,712,000	-2,751,000	14,435,000	26,118,000	1,030,000	11,907,000	14,023,000	3,544,000
accrued expenses, deferred revenue, and other liabilities	7,999,000	38,195,000
net cash from operating activities from continuing operations	110,029,000	114,047,000	113,690,000	80,043,000													215,037,000	76,188,000	85,395,000	30,782,000	91,806,000	31,061,000	120,942,000	96,079,000
net cash from operating activities from discontinued operations	-2,044,000	82,000	-2,022,000	-12,396,000																	298,000	-690,000	-1,168,000	11,196,000
net cash from operating activities	107,985,000	114,129,000	111,668,000	67,647,000	106,290,000	154,890,000	-46,496,000	81,876,000	113,365,000	134,453,000	121,974,000	74,751,000	109,445,000	137,262,000	142,340,000	55,187,000	215,037,000	76,188,000	85,395,000	30,782,000	92,104,000	30,371,000	119,774,000	107,275,000	137,203,000	155,827,000	151,982,000	60,327,000	137,972,000	163,219,000	131,482,000	75,033,000	118,036,000	135,847,000	96,537,000	41,827,000	100,533,000	132,101,000	116,117,000	22,719,000	108,483,000	101,860,000	107,842,000	45,873,000	82,253,000	90,173,000
capex	-21,752,000	-21,020,000	-22,159,000	-17,718,000	-13,563,000	-18,558,000	-27,798,000	-21,270,000	-23,838,000	-20,048,000	-19,486,000	-18,930,000	-26,379,000	-18,401,000	-21,610,000	-21,050,000	-21,965,000	-22,047,000	-19,882,000	-24,982,000	-25,071,000	-24,558,000	-22,785,000	-21,983,000	-23,268,000	-22,828,000	-22,227,000	-25,062,000	-27,420,000	-26,638,000	-21,975,000	-16,647,000	-19,480,000	-17,567,000	-17,359,000	-16,966,000	-22,306,000	-15,802,000	-21,741,000	-17,141,000	0	-18,653,000	-18,051,000	-14,360,000	-15,898,000	-13,823,000
free cash flows	86,233,000	93,109,000	89,509,000	49,929,000	92,727,000	136,332,000	-74,294,000	60,606,000	89,527,000	114,405,000	102,488,000	55,821,000	83,066,000	118,861,000	120,730,000	34,137,000	193,072,000	54,141,000	65,513,000	5,800,000	67,033,000	5,813,000	96,989,000	85,292,000	113,935,000	132,999,000	129,755,000	35,265,000	110,552,000	136,581,000	109,507,000	58,386,000	98,556,000	118,280,000	79,178,000	24,861,000	78,227,000	116,299,000	94,376,000	5,578,000	108,483,000	83,207,000	89,791,000	31,513,000	66,355,000	76,350,000
investing activities
purchases of property and equipment	-21,752,000	-21,020,000	-22,159,000	-17,718,000	-13,563,000	-18,558,000	-27,798,000	-21,270,000	-23,838,000	-20,048,000	-19,486,000	-18,930,000	-26,379,000	-18,401,000	-21,610,000	-21,050,000	-21,965,000	-22,047,000	-19,882,000	-24,982,000	-25,071,000	-24,558,000	-22,785,000	-21,983,000	-23,268,000	-22,828,000	-22,227,000	-25,062,000	-27,420,000	-26,638,000	-21,975,000	-16,647,000	-19,480,000	-17,567,000	-17,359,000	-16,966,000	-22,306,000	-15,802,000	-21,741,000	-17,141,000		-18,653,000	-18,051,000	-14,360,000	-15,898,000	-13,823,000
proceeds from sale of assets	0																				0	0	0	3,632,000
acquisition of businesses, net of cash acquired																	-3,311,000	-80,361,000			-25,294,000
sale of investment in unconsolidated affiliates					0
net cash from investing activities	-61,600,000	-618,000	-22,159,000	-17,718,000	-13,563,000	-5,835,000	-27,798,000	-21,270,000	-23,838,000	-22,318,000	-207,236,000	-20,230,000	-26,379,000	-44,401,000	-21,610,000	-47,050,000	-25,277,000	-102,408,000	-21,930,000	-24,953,000	-50,368,000	-86,177,000	-57,511,000	-28,266,000	2,915,000	-25,670,000	-81,653,000	-25,062,000	-27,420,000	-26,638,000	-21,976,000	-16,646,000	-17,872,000	-110,823,000	-239,555,000	-96,803,000	1,495,000	19,642,000	5,856,000	-186,629,000	-82,716,000	-38,340,000	-50,229,000	-60,588,000	-71,671,000	-76,356,000
financing activities
payments on notes payable	-25,555,000	-25,439,000	-25,323,000	-26,214,000	-25,091,000	-24,974,000	-25,049,000	-25,823,000
proceeds from credit facility	95,000,000	240,000,000							120,000,000	65,000,000	185,000,000	100,000,000	25,000,000	125,000,000	0	175,000,000	0	100,000,000	25,000,000	100,000,000	25,000,000	250,000,000			0				0	0			0	97,500,000			0	0	0	150,000,000
payments on credit facility	-70,000,000				0	0	0	-215,000,000	-140,000,000	-130,000,000			-125,000,000	0	-50,000,000	-75,000,000	-125,000,000	0	-75,000,000	-25,000,000	-200,000,000	-50,000,000	-75,000,000	-25,000,000					-100,000,000	0	0	-50,000,000	-147,500,000				-50,000,000
proceeds from sale of future revenues	0	0	0	42,325,000	51,607,000	0	50,837,000	578,983,000
payments on liability related to the sale of future revenues	-12,514,000	-11,165,000	-8,479,000	-20,949,000	-7,372,000	-9,552,000	-10,289,000	-4,322,000
cash dividends paid	-17,758,000	-17,319,000	-21,045,000	-21,323,000	-22,133,000	-22,015,000	-25,232,000	-25,827,000	-25,006,000	-25,022,000	-24,987,000	-25,218,000	-23,594,000	-23,817,000	-24,192,000	-24,852,000	-23,251,000	-23,251,000	-23,201,000	-23,195,000
repurchase of class a common stock	1,000	-210,438,000	-133,314,000	-56,440,000	0								0	-76,213,000	-135,765,000	-38,151,000					0	-1,527,000	-117,443,000	-31,123,000	-1,293,000	-144,552,000	-91,975,000	-12,313,000	0	-129,285,000
payments on deferred consideration related to acquisition of business
payments on earn-out liabilities	0
net cash from financing activities	-34,012,000	-128,032,000	-90,549,000	-88,140,000	-29,409,000	-458,293,000	-7,883,000	302,865,000	-91,230,000	-115,266,000	3,254,000	35,976,000	-176,420,000	477,000	-218,989,000	47,143,000	-193,203,000	49,791,000	-74,868,000	15,283,000	-184,166,000	185,970,000	-75,937,000	-94,820,000	-136,575,000	-103,229,000	-102,167,000	-45,229,000	-107,576,000	-150,185,000	-78,612,000	-83,002,000	-179,647,000	-7,698,000	205,898,000	-37,829,000	-91,595,000	-70,769,000	-74,398,000	127,223,000	-34,881,000	-37,500,000	-22,519,000	-22,549,000	-30,836,000	-19,836,000
effect of exchange rate changes on cash flows	25,000	-2,000	-66,000	21,000	-28,000	-16,000	26,000	-3,000	3,000	1,000	1,000	-10,000	-6,000	4,000
net increase in cash and cash equivalents			-1,106,000	-38,190,000	63,290,000	-309,254,000	-82,151,000	363,468,000	-1,700,000	-3,130,000	-82,007,000	90,487,000	-93,360,000	93,342,000	-98,260,000	55,280,000	-3,443,000	23,571,000	-11,403,000	21,112,000													-79,483,000	17,326,000			10,433,000	80,974,000			-9,114,000
cash and cash equivalents at beginning of period	0	0	0	125,146,000	0	0	0	89,793,000		0	0	86,143,000		0	0	129,141,000																						0	0	146,522,000		0	0	131,786,000
cash and cash equivalents at end of period	12,398,000	-14,523,000	-1,106,000	86,956,000	63,290,000	-309,254,000	-82,151,000	453,261,000	-1,700,000	-3,130,000	-82,007,000	176,630,000	-93,360,000	93,342,000	-98,260,000	184,421,000	-3,443,000	23,571,000	-11,403,000	120,416,000	-142,430,000			125,244,000		26,928,000	-31,838,000	142,422,000		-13,604,000	30,894,000	132,120,000		17,326,000				80,974,000	47,575,000	109,835,000		26,020,000	35,094,000	94,522,000
net decrease in cash and cash equivalents																							-13,674,000	-15,811,000	3,543,000			-9,964,000				-24,615,000				-92,805,000				-36,687,000			35,094,000	-37,264,000	-20,254,000
accrued expenses, deferred revenue and other liabilities				-80,804,000	4,139,000	5,103,000	-89,668,000	124,948,000
equity in net income (income) of unconsolidated affiliates					-1,344,000	-753,000	666,000	1,726,000
gain on fff put and call rights																	5,731,000	5,195,000				13,906,000
inventory					-2,004,000	-5,029,000	-2,898,000	7,064,000																														937,000	1,645,000	1,169,000
acquisition of businesses and equity method investments, net of cash acquired									0	0			0	0	0	-26,000,000
investment in unconsolidated affiliates									0				0																				0	0	0	-65,660,000	0	-2,250,000
proceeds from exercise of stock options under equity incentive plan									5,374,000	0	60,000	644,000											4,244,000	1,754,000		5,191,000	4,651,000	7,472,000		807,000	156,000	2,652,000		413,000	592,000	2,317,000		2,282,000	40,000	197,000		630,000
equity in net income of unconsolidated affiliates									-1,521,000	-4,630,000	-1,674,000	-8,243,000	-6,340,000	-3,991,000	-6,116,000	-7,058,000	-5,050,000	-5,524,000	-4,572,000	-5,927,000	-1,499,000	-4,442,000	-2,989,000	-3,607,000	-971,000	-553,000	-1,444,000	-2,690,000	-604,000	4,939,000	-1,257,000	-4,252,000	44,000	-83,000	-5,127,000	-9,579,000	-5,645,000	-6,627,000	-4,785,000	-4,590,000	-6,473,000	-5,197,000	-4,749,000	-4,866,000	-4,805,000	-3,566,000
(gain) loss on fff put and call rights																										4,109,000
accounts receivable, inventories, prepaid expenses and other assets									16,864,000	31,618,000	-6,724,000	22,495,000	33,241,000	41,254,000	27,482,000	22,682,000	113,255,000	-53,499,000	-82,295,000	-45,469,000	-25,782,000	-90,201,000	-12,724,000	6,972,000
accounts payable, accrued expenses, deferred revenue, revenue share obligations and other liabilities									-71,827,000	32,559,000	43,500,000	-23,822,000	-21,787,000	9,859,000			-6,052,000	51,529,000	68,025,000	20,577,000	-7,012,000	-2,894,000	3,383,000	-23,830,000
payments made on notes payable									-24,835,000	-24,975,000	-24,662,000	-26,387,000	-24,161,000	-24,461,000	-23,929,000	-26,692,000	-19,021,000	-28,008,000	-3,496,000	-188,000	-373,000	-1,000	-532,000	-1,513,000					-5,000	-1,139,000	-1,884,000	-4,974,000	-2,150,000	-1,998,000	-1,120,000	-218,000	-296,000	-511,000	-1,006,000	-330,000	-357,000	-362,000	-362,000	-322,000	-4,176,000	-3,195,000
distributions to limited partners of premier lp																	0	0	0	-9,949,000	-9,314,000	-12,689,000	-13,699,000	-13,202,000	-13,079,000	-14,288,000	-14,993,000	-15,465,000	-13,157,000	-20,395,000	-20,752,000	-24,951,000	-23,071,000	-22,733,000	-22,137,000	-22,493,000	-24,742,000	-22,504,000	-23,029,000	-22,432,000	-23,412,000	-23,701,000	-22,691,000	-22,408,000	-21,299,000	-17,419,000
payments to limited partners of premier lp related to tax receivable agreements																	0	0	0	-24,218,000	0	0	0	-17,425,000	0	0	0	-17,975,000
cash and cash equivalents at beginning of year																	0	0	0	99,304,000	0			141,055,000	0	0	0	152,386,000	0	0	0	156,735,000	0	0	0	248,817,000									0	0
income from discontinued operations, net of tax
remeasurement of tax receivable agreement liabilities																					0	-902,000	-28,356,000	4,674,000					0	0
(gain) loss on fff call/put rights														0	0	-64,110,000
proceeds from exercise of stock options														118,000
accounts payable, accrued expenses, deferred revenue, revenue share obligations and other current liabilities																-70,014,000
(income) income from discontinued operations, net of tax																					-45,000	-5,000	-614,000	-390,000
impairment of held to maturity investments																					0
net cash from investing activities from continuing operations																					-50,368,000	-86,177,000
net cash from investing activities from discontinued operations
investments in unconsolidated affiliates																					0	0	-5,500,000	-4,665,000
loss on fff put and call rights																				1,919,000				7,839,000				3,283,000	3,362,000	3,067,000
earn-out liability payment to gnyha holdings																													0	0
other operating activities																						-893,000	409,000	2,562,000	243,000	2,021,000	116,000	382,000	-322,000	19,000	184,000	6,422,000	7,352,000	-4,526,000	550,000	-387,000	1,588,000	-829,000	843,000	-535,000	690,000	670,000	555,000	596,000	2,046,000	-320,000
other investing activities																						0	5,501,000	-5,250,000	24,000							1,000	0	-1,000	21,000	5,000	74,000	-96,000	-439,000	434,000		-796,000	-128,000	481,000
other financing activities																																							193,000	-174,000
changes in operating assets and liabilities:
acquisition of stanson health, inc., net of cash acquired																									0	72,000
acquisition of medpricer.com, inc., net of cash acquired
redemption of limited partner of premier lp																									0	512,000
proceeds from issuance of class a common stock under employee stock purchase plan
repurchase of vested restricted units for employee tax-withholding																							-47,000	-8,311,000	-12,000	-92,000	-1,082,000	-6,948,000	-49,000	-173,000	-14,000	-5,729,000	-39,000	-49,000	-194,000	-17,435,000
remeasurement gain attributable to acquisition of innovatix, llc																																		0
loss on disposal of long-lived assets																									6,378,000				651,000	5,000	400,000	1,320,000	179,000	725,000	0	1,518,000
accounts receivable, prepaid expenses and other current assets																													-10,733,000	-3,091,000	8,281,000	-8,748,000	-3,672,000	18,925,000	-3,769,000	-8,119,000	-10,179,000	-826,000	-6,106,000	-20,139,000	4,681,000	-12,369,000	6,314,000	-17,590,000	-1,052,000	-426,000
inventories																									239,000	5,257,000	-1,796,000	-2,097,000	-8,909,000	4,837,000	-4,463,000	-7,178,000	-1,656,000	17,139,000	-31,005,000	-827,000						-2,181,000	-5,197,000	-1,657,000	-1,543,000	-3,164,000
other assets																									-4,358,000	-4,528,000	5,117,000	-2,235,000	-1,202,000	-682,000	-319,000	1,379,000	6,416,000	131,000	1,386,000	-1,112,000	135,000	1,080,000	1,433,000	-12,286,000	-606,000	2,624,000	-3,882,000	128,000	69,000	2,000
accounts payable, deferred revenue and other current liabilities
accrued expenses
long-term liabilities																									2,166,000	4,810,000	-7,019,000	-14,000	5,337,000	49,000	1,398,000	-111,000	320,000	2,879,000	-4,422,000	322,000	-2,949,000	-1,412,000	447,000	-281,000	374,000	1,743,000	1,699,000	-1,025,000	-3,577,000	313,000
acquisition of innovatix, llc and essensa ventures, llc, net of cash acquired																																		-97,500,000
acquisition of acro pharmaceuticals, net of cash acquired
investments in convertible notes																									0	-3,000,000
cancellation of convertible note
proceeds from sale of marketable securities																																	0	0	0	48,013,000	18,772,000	27,926,000	31,940,000	307,734,000	87,031,000	108,023,000	52,074,000	138,660,000	76,560,000	33,770,000
distributions received on equity investments in unconsolidated affiliates
premier, inc.
consolidated statements of cash flows
proceeds from exercise of stock options under equity incentive plans
proceeds from issuance of class a common stock under stock purchase plan																													1,231,000	0			1,227,000	0			1,015,000	0
settlement of exchange of class b units by member owners																																	-1,000	-23,331,000
cash and cash equivalents at end of year																																				156,012,000									-20,254,000	-6,019,000
supplemental schedule of non cash investing and financing activities:
increase in redeemable limited partners' capital for adjustment to fair value, with offsetting decrease (increase) in additional paid-in-capital and accumulated deficit
reduction in redeemable limited partners' capital, with offsetting increase in common stock and additional paid-in capital related to quarterly exchange by member owners																																								-3,268,000
reduction in redeemable limited partners' capital for limited partners' distribution payable																																		112,811,000						23,028,000				22,691,000	999,000	3,933,000
distributions utilized to reduce subscriptions, notes, interest and accounts receivable from member owners																																	488,000	487,000						1,613,000				3,112,000	27,000	14,000
net increase in deferred tax assets related to quarterly exchanges by member owners and other adjustments																																	20,011,000
net increase in tax receivable agreement liabilities related to quarterly exchanges by member owners and other adjustments
net increase in additional paid-in capital related to quarterly exchanges by member owners and other adjustments
net increase in investments in unconsolidated affiliates related to deferred taxes attributed to the net fair value of fff enterprises, inc. put and call rights, with offsetting increases in deferred tax assets and deferred tax liabilities
payable to member owners incurred upon repurchase of ownership interest																																	284,000							373,000				1,515,000	129,000	0
accounts receivable, contract assets, prepaid expenses and other current assets																										-11,000	-15,448,000	-41,427,000
accounts payable, accrued expenses, deferred revenue and other current liabilities																										22,507,000	37,142,000	-21,776,000
accounts payable, accrued expenses and other current liabilities																													23,077,000	29,928,000	1,695,000	-21,933,000	-13,400,000	-6,946,000	34,327,000	-38,463,000
purchase of marketable securities																																					0	0	0	-19,211,000	-155,520,000	-116,246,000	-89,124,000	-34,412,000	-131,713,000	-138,001,000
acquisition of cecity.com, inc., net of cash acquired																																					0	0	0	-398,261,000
acquisition of healthcare insights, llc, net of cash acquired																																					0	360,000	0	-64,634,000
acquisition of inflowhealth, llc																																					0
final remittance of net income attributable to former s2s global minority shareholder																																					0
adjustment to tax receivable agreement liability																																		2,768,000	0	-5,722,000	0	0	0	-4,818,000			0	1,073,000
loss on investment
adjustment to tax receivable agreement liabilities
remeasurement gain attributable to acquisition of innovatix
acquisition of innovatix and essensa, net of cash acquired
acquisition of cecity, net of cash acquired
acquisition of hci, net of cash acquired
acquisition of inflow
acquisition of aperek, net of cash acquired																																										0	0	-47,446,000
acquisition of theradoc, net of cash acquired																																										0	0	-108,561,000
purchase of non-controlling interest in s2s global
distributions received on equity investment																																			0	6,550,000	5,050,000	5,300,000	6,293,000	5,450,000	5,000,000	3,850,000	5,000,000	5,050,000	5,000,000	3,850,000
decrease in restricted cash
proceeds from s2s global revolving line of credit																																									0	207,000	600,000	200,000
payments on s2s global revolving line of credit																																									0	-14,215,000
reduction in redeemable limited partners' capital for limited partners' capital distribution payable
increase in additional paid-in capital related to quarterly exchanges by member owners
net increase in investments in unconsolidated affiliates related to fff put and call rights, with offsetting increases in other assets and other liabilities
acquisition of acro pharmaceutical services llc and community pharmacy services, llc, net of cash acquired																																		4,245,000	0	-68,745,000
acquisition of inflow health, llc
decrease in redeemable limited partners' capital for adjustment to fair value, with offsetting decreases in additional paid-in-capital and accumulated deficit
reduction in redeemable limited partners' capital, with offsetting increases in common stock and additional paid-in capital related to quarterly exchanges by member owners
net increase in tax receivable agreement liability related to quarterly exchanges by member owners and other adjustments
net increase in investments in unconsolidated affiliates related to fff enterprises, inc. put and call rights, with offsetting increases in other assets and other liabilities
decrease in redeemable limited partners' capital for adjustment to fair value, with offsetting decrease in additional paid-in-capital and accumulated deficit
reduction in redeemable limited partners' capital, with offsetting increase in common stock and additional paid-in capital related to quarterly exchanges by member owners
increase in deferred tax assets related to quarterly exchanges by member owners
increase in tax receivable agreement liability related to quarterly exchanges by member owners
reduction in deferred tax assets related to departed member owners																																								312,000
reduction in tax receivable agreement liability related to departed member owners																																								789,000
gain on investment																																									0
proceeds from sale of investment in ghx
acquisition of aperek, inc., net of cash acquired
acquisition of theradoc, inc., net of cash acquired
acquisition of symmedrx, net of cash acquired																																													0	-2,000
acquisition of meddius, l.l.c, net of owner note receivable
acquisition of memdata, llc, net of cash acquired
payments made in connection with the origination of the credit facility
proceeds from issuance of class a common stock in connection with the ipo, net of underwriting fees and commissions
payments made in connection with the ipo
purchases of class b common units from member owners																																													0	0
proceeds from issuance of pshi common stock
proceeds from notes receivable from partners																																													-21,000	-20,000
issuance of limited partnership interest for notes receivable																																													0	0
reduction in redeemable limited partners' capital to reduce outstanding receivable																																													0	0
distributions and notes payable utilized to reduce subscriptions, notes, interest and accounts receivable from member owners
increase in redeemable limited partners' capital for adjustment to redemption amount, with offsetting decrease in additional paid-in capital and accumulated deficit
increase in additional paid-in capital related to quarterly exchanges by member owners and departure of member owners
increase in deferred tax assets related to purchase of non-controlling interest in s2s global
increase in deferred tax assets and additional paid-in capital related to the reorganization
increase in payables and decrease in additional paid-in capital pursuant to the tax receivable agreements
reduction in prepaid expenses and other current assets for ipo costs capitalized to additional paid-in capital
accounts payable, accrued expenses, revenue share obligations and other current liabilities																																						33,826,000	20,334,000	-32,710,000	25,164,000	24,424,000	28,978,000	-17,732,000	-5,268,000
purchase of noncontrolling interest in s2s global																																									0
proceeds from sale of property and equipment
repurchase of restricted units																																						-17,000	-8,000	-38,000	-45,000	-59,000	-12,000	-19,000	-7,000	-2,000
employee stock purchase plan expense
payments on senior secured line of credit																																													0	0
final remittance of net income attributable to s2s global before february 1, 2015
investment in unconsolidated affiliate																																								-1,000,000
supplemental schedule of non-cash investing and financing activities:
increase in redeemable limited partners' capital for adjustment to redemption amount, with offsetting increase in additional paid-in-capital and accumulated deficit																																								-466,801,000
increase in additional paid-in capital related to quarterly exchange by member owners and departure of member owners																																								879,000
increase in tax receivable agreement liability related to quarterly exchange by member owners																																								1,013,000
increase in deferred tax assets related to quarterly exchange by member owners																																								1,415,000
proceeds from sale of investment in global healthcare exchange, llc																																													522,000
acquisition of meddius, l.l.c., net of owner note receivable																																													0	0
capital expenditures
proceeds from senior secured line of credit																																													0	0
payments made in connection with the origination of credit facility
proceeds from issuance of phsi common stock																																													0	0
proceeds from issuance of redeemable limited partnership interest
deferred taxes																																										-1,186,000	-3,492,000	4,409,000	6,987,000	240,000
increase in redeemable limited partners' capital for adjustment to redemption amount, with offsetting decrease in additional paid-in-capital and accumulated deficit																																												382,657,000
reduction in prepaid expenses and other current assets for ipo costs capitalized to additional paid-in-capital																																														154,000
gain on sale of investment																																													-522,000
increase in redeemable limited partners' capital for adjustment to redemption amount, with offsetting decrease in additional paid-in-capital and retained earnings																																													-461,161,000	-517,063,000
proceeds from svs, llc revolving line of credit																																														800,000
proceeds from issuance of class a common stock in connection with the ipo, net of expenses																																														0
increase in deferred tax assets and additional paid-in-capital related to the reorganization																																														0
increase in payables and decrease in additional paid-in-capital pursuant to the tax receivable agreement																																														0
issuance of common stock for subscriptions receivable

We provide you with 20 years of cash flow statements for Premier stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Premier stock. Explore the full financial landscape of Premier stock with our expertly curated income statements.

The information provided in this report about Premier stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.